Mankind Pharma Ltd Analyst Rating
based on 16 analysts
75.00%
Buy
18.75%
Hold
6.25%
Sell
Based on 16 analysts offering long term price targets for Mankind Pharma Ltd. An average target of ₹2814.88
Source: S&P Global Market Intelligence
Mankind Pharma Ltd Share analysis
Mankind Pharma Ltd price forecast by 16 analysts
Downside of
High
₹3300
Target
₹2814.88
Low
₹2275
Mankind Pharma Ltd target price ₹2814.88, a slight downside of -4.18% compared to current price of ₹2884.55. According to 16 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Mankind Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2027:67.87%
Forecast
Actual
Including amortisation and stock based compensations
Mankind Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2027:58.37%
Forecast
Actual
Source: S&P Global Market Intelligence
Mankind Pharma Ltd Performance
Day's Low
Day's High
₹2,864Day's Price Range₹2,998.452 Week's Low
52 Week's High
₹1,901.0552-Week Price Range₹3,054.8
| Returns % | |
| 1 Month Return | + 13.57 % |
| 3 Month Return | + 14.67 % |
| 1 Year Return | + 46.88 % |
| Market Stats | |
| Previous Close | ₹2,937.55 |
| Open | ₹2,944.50 |
| Volume | 6.93L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,21,193.59Cr |
Mankind Pharma Ltd Key Statistics
| P/E Ratio | 55.65 |
| PEG Ratio | 4 |
| Market Cap | ₹1,21,193.59 Cr |
| P/B Ratio | 9.56 |
| EPS | 48.47 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 20.95 |
Mankind Pharma Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹1,21,193.59 Cr | 21.31% | 0.51 | ₹1,941 Cr | ₹10,334 Cr | |
| BUY | ₹4,43,792.99 Cr | 64.08% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| BUY | ₹1,22,050.67 Cr | 44.76% | 0.50 | ₹4,155 Cr | ₹25,774 Cr | |
| HOLD | ₹1,60,563.36 Cr | 45.8% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,15,162.73 Cr | 52.16% | 0.67 | ₹1,656 Cr | ₹10,727 Cr |
About Mankind Pharma Ltd
Share Price: ₹2884.55 per share as on 06 Jan, 2025 04:04 PM
Market Capitalisation: ₹1,21,193.59Cr as of today
Revenue: ₹3,076.51Cr as on September 2024 (Q3 24)
Net Profit: ₹658.88Cr as on September 2024 (Q3 24)
Listing date: 09 May, 2023
Chairperson Name: RAMESH CHAND JUNEJA
| Organisation | Mankind Pharma Ltd |
| Headquarters | New Delhi |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Mankind Pharma Ltd
Mankind Pharma Downgraded Despite Strong Performance - 01 Jan, 2025
Mankind Pharma received a 'Hold' downgrade from MarketsMojo on January 1, 2025, despite strong financials, including an 18.64% ROE and significant market outperformance. The company reported impressive cash flow and sales figures, but its high valuation remains a concern.Mankind Pharma Partners for Sintilimab in India - 26 Dec, 2024
Mankind Pharma has partnered with Innovent Biologics to exclusively license and commercialize sintilimab in India. The company plans to file for regulatory approval and conduct a phase 3 clinical trial to enhance cancer treatment access.Mankind Pharma Faces Profit Booking After QIP Listing - 24 Dec, 2024
Mankind Pharma's stock dipped 5% due to profit booking following the listing of QIP shares. Despite this, the company shows strong market leadership and growth potential.Mankind Pharma Stock Poised for Growth - 19 Dec, 2024
Mankind Pharma Ltd has outperformed the index and is expected to reach new highs. Analysts suggest a buy with a target of 3150, anticipating a 10-12% upside from current levels, with a stop loss at 2700.Mankind Pharma Launches QIP for BSV Acquisition - 16 Dec, 2024
Mankind Pharma is set to launch a Qualified Institutional Placement (QIP) to raise up to ₹3,000 crore, primarily to fund the ₹13,630 crore acquisition of Bharat Serums and Vaccines. The company reported strong financial growth, with a 30.4% YoY increase in net profit for Q2 FY25.Mankind Pharma Reports Growth Amid GST Dispute - 13 Dec, 2024
Mankind Pharma announced a 13.6% YoY revenue increase and improved profitability metrics. However, it faces a GST order deemed unjustified for previous fiscal years.
Insights on Mankind Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 3 quarters, 2.53K Cr → 3.18K Cr (in ₹), with an average increase of 10.7% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 12.37% to 13.35% in Dec 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 2.86% to 2.92% in Dec 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 453.76 Cr → 653.47 Cr (in ₹), with an average increase of 11.3% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 6.99% to 7.97% in Dec 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 1 month, MANKIND stock has moved up by 13.6%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 74.87% to 72.71% in Dec 2024 quarter
Mankind Pharma Ltd Financials
Index Inclusions
Mankind Pharma Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 72.71% | ||
| Foreign Institutions | 13.35% | 7.91 | |
| Mutual Funds | 7.97% | 14.10 | |
| Retail Investors | 2.92% | 2.22 | |
| Others | 3.05% | 4.68 |
Mankind Pharma Ltd Key Indicators
Mankind Pharma Ltd Valuation
Mankind Pharma Ltd in the last 5 years
Lowest (40.63x)
August 5, 2024
Today (55.65x)
January 3, 2025
Industry (58.82x)
January 3, 2025
Highest (56.80x)
December 23, 2024
Mankind Pharma Ltd Earnings and Dividends
Mankind Pharma Ltd Earnings Results
Mankind Pharma Ltd’s net profit jumped 30.43% since last year same period to ₹653.47Cr in the Q2 2024-2025. On a quarterly growth basis, Mankind Pharma Ltd has generated 21.8% jump in its net profits since last 3-months.
Read More about Earnings Results
Mankind Pharma Ltd Technicals Summary
Bearish
Neutral
Bullish
Mankind Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Mankind Pharma Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Mankind Pharma Ltd shares.
Mankind Pharma Ltd (MANKIND) share price today is ₹2884.55
Mankind Pharma Ltd is listed on NSE
Mankind Pharma Ltd is listed on BSE
- Today’s highest price of Mankind Pharma Ltd is ₹2998.4.
- Today’s lowest price of Mankind Pharma Ltd is ₹2864.
PE Ratio of Mankind Pharma Ltd is 55.65
PE ratio = Mankind Pharma Ltd Market price per share / Mankind Pharma Ltd Earnings per share
Today’s traded volume of Mankind Pharma Ltd(MANKIND) is 6.93L.
Today’s market capitalisation of Mankind Pharma Ltd(MANKIND) is ₹121193.59Cr.
| Mankind Pharma Ltd(MANKIND | Price |
|---|---|
52 Week High | ₹3054.8 |
52 Week Low | ₹1901.05 |
Mankind Pharma Ltd(MANKIND) share price is ₹2884.55. It is down -5.57% from its 52 Week High price of ₹3054.8
Mankind Pharma Ltd(MANKIND) share price is ₹2884.55. It is up 51.73% from its 52 Week Low price of ₹1901.05
| Mankind Pharma Ltd(MANKIND | Returns |
|---|---|
1 Day Returns | -53% |
1 Month Returns | 13.57% |
3 Month Returns | 14.67% |
1 Year Returns | 46.88% |